El Instituto de Salud Carlos III utiliza cookies propias y de terceros para el correcto funcionamiento y visualización del sitio web por parte del usuario, así como la recogida de estadísticas. Si continúa navegando, consideramos que acepta su uso. Para más información visite nuestra Política de Cookies.
Ver más información

We protect your health through science

Search Bar

Usa comillas para buscar una secuencia de palabras exacta. Ej: "Proyectos Financiados"

Investigation

Bacterial Genetics

Research Lines

Content with Investigacion Taxonomía Bacteriana .

Taxonomía Bacteriana

null

Research projects

Content with Investigacion Taxonomía Bacteriana .

- Título: Desvelando la genómica de las bacterias anaerobias procedentes de bacteriemias
Referencia Proyecto: PID202-1127477OB-I00-MPY 302/22.
Entidad financiador: Agencia Estatal de Investigación.
Fechas de ejecución: 2023-2026
Financiación 108.900 €.
Investigadora principal: Sylvia Valdezate


 

- Título: Plataformas MALDI-TOF/CMI SENSITITRETM Personal Técnico Apoyo
Referencia: PTA2019-016623-I. 
Entidad Financiadora: Agencia Estatal de Investigación. 
Fechas ejecución 12/2020-11/2023
Investigadora principal: Sylvia Valdezate

- Título: Elementos genéticos móviles protagonistas en la evolución de los serotipos pandémicos M1 y M89 de Streptococcus pyogenes en el síndrome del shock tóxico y otras infecciones invasivas
Referencia: (MPY 377/18).
Entidad financiadora: Instituto de Salud Carlos III. Agencia Estatal de Investigación en Salud Intramural (AESI). 
Fechas de ejecución: 11/2018-12/2022. 
Financiación: 40.000 €.
Investigadoras principales: Pilar Villalón. Co-IP Sylvia Valdezate. 

- Título: Plataformas genéticas y su influencia en la resistencia a co-trimoxazol, macrólidos y tetraciclina en Nocardia spp.
Referencia: MPY 1278/15
Entidad financiadora: Instituto de Salud Carlos III. Agencia Estatal de Investigación en Salud Intramural (AESI).
Fechas de ejecución: 2015-2017.
Financiación: 88.141,8 €. 
Investigadora principal: Sylvia Valdezate

- Título: Filogenia y caracterización de mecanismos moleculares de resistencia en Nocardia spp. 
Referencia: MPY 1446/11
Entidad financiadora: Instituto de Salud Carlos III. Fondo de Investigación Sanitaria (AES). () 
Fechas de ejecución: 04/2012-10/2015
Financiación: 115.457 €. 
Investigadora principal: Sylvia Valdezate.

- Título: Iberian network of laboratories of biological alert. Accreditation of methods for detection highly pathogenic agents (IB-BIOALERTNET). 
Entidad financiadora: COMISIÓN EUROPEA HOME/2012/ISEC/AG/CBRN/4000003810. (Instituto de Salud Carlos III (VISAVET, IVIA, INSA, INIAV))
Referencia: SAFI 1132/13-7. 
Fecha de ejecución: 2013-2015.
Financiación: 699.175 €. 
Tipo de participación: Miembro del equipo investigador.

- Título: EQUATOX Project Establishment of Quality Assurances for theDetection of Biological Toxins of potential Bioterrorism risk. 
Entidad financiadora y convocatoria: Seven Framework Programme for Research FP7-SECURITY. (Robert Koch-Institut Berlin Alemania). 
Referencia: SEC-2011.5.4-1. 
Fechas de ejecución: 2012-2014.

Search Bar

Publications

Sort
Category

Monocyte-Derived Suppressor Cells in Transplantation

8. Ochando J, Conde P, Bronte V. 2015. Monocyte-Derived Suppressor Cells in Transplantation. Curr Transplant Rep. 2015;2(2):176-183.

PUBMED DOI

DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance

9. Conde P, Rodriguez M, van der Touw W, Jimenez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, Yun TJ, Riquelme P, Rastrojo A, Aguado B, Stein-Streilein J, Tanaka M, Zhou L, Zhang J, Lowary TL, Ginhoux F, Park CG, Cheong C, Brody J, Turley SJ, Lira SA, Bronte V, Gordon S, Heeger PS, Merad M, Hutchinson J, Chen SH, Ochando J. 2015. DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance. Immunity. 16;42(6):1143-58.

PUBMED DOI

Proteomic characterisation of bovine and avian purified protein derivatives and identification of specific antigens for serodiagnosis of bovine tuberculosis

2.- Proteomic characterisation of bovine and avian purified protein derivatives and identification of specific antigens for serodiagnosis of bovine tuberculosis. Antonio Infantes-Lorenzo, Jose; Moreno, Inmaculada; Angeles Risalde, Maria; et ál. CLINICAL PROTEOMICS Volumen: 14 Número de artículo: 36 Fecha de publicación: NOV 2 2017

PUBMED DOI

Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.

3.- Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications. Subias Hidalgo, Marta; Yebenes, Hugo; Rodriguez-Gallego, Cesar; et ál..EUROPEAN JOURNAL OF IMMUNOLOGY Volumen: 47 Número: 3 Páginas: 504-515 Fecha de publicación: MAR 2017

PUBMED DOI

Immunoproteomic characterisation of Mycoplasma mycoides subspecies capri by mass spectrometry analysis of two- dimensional electrophoresis spots and western blot

5.- Immunoproteomic characterisation of Mycoplasma mycoides subspecies capri by mass spectrometry analysis of two- dimensional electrophoresis spots and western blot. Churchward, Colin P.; Rosales, Ruben S.; Gielbert, Adriana; et ál..JOURNAL OF PHARMACY AND PHARMACOLOGY Volumen: 67 Número: 3 Número especial: SI Páginas: 364-371 Fecha de publicación: MAR 2015

PUBMED DOI

Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.

6.- Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis. Corral, M. Jesus; Serrano, Dolores R.; Moreno, Inmaculada; et ál..JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY Volumen: 69 Número: 12 Páginas: 3268-3274 Fecha de publicación: DEC 2014

PUBMED DOI

A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models

7.- A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models. Subias, Marta; Tortajada, Agustin; Gastoldi, Sara; et ál..JOURNAL OF IMMUNOLOGY Volumen: 193 Número: 11 Páginas: 5567-5575 Fecha de publicación: DEC 2014

PUBMED DOI

Detection of anti-Leishmania infantum antibodies in sylvatic lagomorphs from an epidemic area of Madrid using the indirect immunofluorescence antibody test

8.- Detection of anti-Leishmania infantum antibodies in sylvatic lagomorphs from an epidemic area of Madrid using the indirect immunofluorescence antibody test. Moreno, Inmaculada; Alvarez, Julio; Garcia, Nerea; et ál..VETERINARY PARASITOLOGY Volumen: 199 Número: 3-4 Páginas: 264-267 Fecha de publicación: 2014

PUBMED DOI

Content with Investigacion Taxonomía Bacteriana .

List of staff

Additional Information

Streptococcus pneumoniae is a human pathogen that, despite the development of vaccines, continues to be an important cause of mortality and morbidity. We investigate the mechanisms of antibiotic resistance in this bacterium. On the one hand by identifying new therapeutic targets and on the other hand by investigating the molecular basis of the action of antibiotics already used in clinical practice (the fluoroquinolones levofloxacin and moxifloxacin) or not yet used (seconeolitsine). For this purpose, we used a multidisciplinary analysis involving genomics, transcriptomics and proteomics to understand the organization of the S. pneumoniae chromosome and the identification of the factors that stabilize this organization, including ncRNAs. Changes in the level of global supercoiling, either by inhibition of gyrase (decrease) or by inhibition of topoisomerase I (increase) alter the transcriptome. The modulated genes are located in domains, whose genes show specific functional characteristics. The aim is to identify new factors essential for S. pneumoniae physiology and to characterize transcriptional regulation in response to topological stress. In addition, RNA interference technology and CRISPR systems will be used as novel antibacterials. These studies will establish the bases for translational research aimed at the development of new therapeutic targets for the treatment of pneumococcal diseases.

Streptococcus pneumoniae is a human pathogen that, despite the development of vaccines, continues to be an important cause of mortality and morbidity. We investigate the mechanisms of antibiotic resistance in this bacterium. On the one hand by identifying new therapeutic targets and on the other hand by investigating the molecular basis of the action of antibiotics already used in clinical practice (the fluoroquinolones levofloxacin and moxifloxacin) or not yet used (seconeolitsine). For this purpose, we used a multidisciplinary analysis involving genomics, transcriptomics and proteomics to understand the organization of the S. pneumoniae chromosome and the identification of the factors that stabilize this organization, including ncRNAs. Changes in the level of global supercoiling, either by inhibition of gyrase (decrease) or by inhibition of topoisomerase I (increase) alter the transcriptome. The modulated genes are located in domains, whose genes show specific functional characteristics. The aim is to identify new factors essential for S. pneumoniae physiology and to characterize transcriptional regulation in response to topological stress. In addition, RNA interference technology and CRISPR systems will be used as novel antibacterials. These studies will establish the bases for translational research aimed at the development of new therapeutic targets for the treatment of pneumococcal diseases.

Content with Investigacion Patógenos Especiales .